Kornimate/medical-research-clean huggingface dataset:
nephrogenic diabetes insipidus during prolonged sevoflurane sedation in the icu: a retrospective analysis

Conditions: Nephrogenic Diabetes Insipidus

Summary: the investigators aim to retrospectively explore the electronic medical records of all patients who were admitted to the intensive care unit (icu) of the uz brussels in the last 10 years (march 1st 2011- march 1st 2021) and who received prolonged sedation (\>24h) with sevoflurane.


Eligibility criteria:
inclusion criteria: * sevoflurane administration \>24h * 18 years and older exclusion criteria: * \< 18 years old * pre-existing diabetes insipidus * use of drugs at risk for diabetes insipidus (including lithium, cisplatin) * hypercalcemia (persistently \>2.75 mmol/l) * pituitary or acute brain surgery * patients requiring continuous renal replacement therapy * pregnancy
evaluation of chlorhexidine plus hyaluronic acid mouthwash in surgical wound healing following third molar surgery (clor_4)

Conditions: Wound Heal; Surgical Wound; Impacted Third Molar Tooth

Summary: evaluation of the response of gingival tissues to the use of mouthwash with chlorhexidine and chlorhexidine + hyaluronic acid in terms of healing of the surgical wound following third molar surgery.

wound healing following third molar surgery will be evaluated at the level of the flap incision. surgical interventions will be performed following a standardized protocol by a single operator. after surgery, patients will be randomly assigned to study groups corresponding to mouth rinse prescription. the mouth rinse will be assigned by an experimenter not involved in the following steps of the study, in order to maintain the examiner blind. the patient will receive a non-labelled mouth rinse to avoid biases both of the examiner and the patient. the patient will also be given a diary for the registration of the number of rinses per day, to be returned to the examiner at t14. the mouth rinse protocol assigned to each study participant includes a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days. the patients will be allocated in one of the three distinct study groups as it follows: group a: administration of 0.2% chlorhexidine + anti-discoloration system + hyaluronic acid mouth rinse (test group 1) group b: administration of 0.2% chlorhexidine + anti-discoloration system mouth rinse (test group 2). group c: administration of placebo mouth rinse (control group) post-treatment photographs of surgical incision will be taken immediately after surgery and at 3 (t3), 7 (t7), and 14 (t14) days post-op, in order to allow the evaluation of the degree of wound healing. the degree of surgical healing will be evaluated using the wound healing index - whi (wachtel classification) on all the incisions, and a score from 1 to 5 will be assigned. at t3, t7, and t14 the following clinical parameters will be recorded for each patient: oedema, trismus and pain level. the clinical examinations will be performed by calibrated examiner blind to group allocation.

Eligibility criteria:
inclusion criteria: * males or females of age range between 18 and 70 years, * good health status, * indication to perform third molar surgery, * patients willing to give informed consent, * compliance to the study follow-up, exclusion criteria: * pregnancy or breast-feeding, * indication to antibiotic therapy prior to surgical treatment, * chronic infections, * systemic diseases (including cardiovascular, pulmonary, cerebral, and metabolic diseases), * previous therapy with the mouth rinses employed in the present study, and * smoking habit (\>20 cigarettes per day, and/or pipe or cigar smoking).

Keywords: chlorhexidine chlorhexidine gluconate anti-infective agents, local wounds and injuries mouth diseases surgical wound wound heal
a novel patient decision aid for surgical treatment options in early-stage breast cancer

Conditions: Breast Cancer

Summary: this is a study to assess the feasibility and acceptability of a novel decision aid (da) in a newly diagnosed, early-stage breast cancer population. insights gained from patient feedback and the implementation process will be used to improve the information delivered in the decision aid itself and to plan for a larger scale trial to compare the decision aid to standard of care.

this pilot study will utilize several tools and instruments to measure various aspects of of the implementation of the decision aid. 1. breast-q patient-reported outcomes, 2. ottawa decision aid evaluation measures, 3. health literacy assessments, 4. distress screening tools, 5. web-based surveys, 6. semi-structured interviews.

Eligibility criteria:
inclusion criteria: * adult women age 18-100 * english speaking * clinical stage 0-iii breast cancer * eligible for both lumpectomy and mastectomy exclusion criteria: * prior surgical consultation regarding treatment options for breast cancer * previous history of breast cancer * requires neoadjuvant chemotherapy prior to surgical intervention

Keywords: early-stage newly diagnosed
virtual reality hypnosis for thoracic drain insertion

Conditions: Pneumopathy

Summary: the main objective of this study is to evaluate, in vigilant resuscitation patients, the effect of the use of hypno vr on the pain felt during the insertion of a thoracic drain.

this is a prospective, randomized, open-label, monocentric, prospective study of two parallel groups of patients in whom a chest tube is to be inserted: * group 1: insertion of the drain according to the usual management protocol. * group 2: insertion of the drain according to the usual management protocol supplemented by the use of a hypnosis software application (hypno-vr).

Eligibility criteria:
inclusion criteria: * patient 18 years of age or older, having read and signed the consent form for participation in the study * patient admitted to intensive care whose state of health requires the insertion of a thoracic drain according to the doctor in charge of the patient. exclusion criteria: * patient under legal protection, guardianship or trusteeship * pregnant or breastfeeding patient * patient not affiliated to the french social security system * hearing or visual disturbances contraindicating the use of virtual reality headphones * inability to provide the subject with informed information and/or written informed consent: dementia, psychosis, consciousness disorders, non-french speaking patient * unbalanced epilepsy * contraindication to local anaesthesia, one of the analgesics or sleeping pills used in the protocol * need for drainage in a life-threatening emergency (respiratory distress or compressive pleural effusion) * concurrent participation in other research or during a period of exclusion from previous research
comparison of two biphasic insulin aspart treatments in subjects with type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe. the aim of this trial is to compare two different active treatment regimens of biphasic insulin aspart in subjects with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * type 2 diabetes * duration of diabetes for longer than 12 months * body mass index (bmi) below 35.0 kg/m\^2 * hba1c below 11.0 % * treatment with bhi (biphasic human insulin) 20 or 30 twice daily for at least three months and in the last month as sole anti-diabetic treatment (i.e., no additional oral hypoglycaemic medication or daily use of short-acting insulin supplement) exclusion criteria: * current treatment with agents affecting glucose metabolism * history of drug or alcohol dependence * impaired hepatic function * impaired renal function * cardiac disease * proliferative retinopathy * recurrent severe hypoglycaemia or advanced neuropathy
renal perfusion and the development of aki following traumatic injury

Conditions: Traumatic Haemorrhagic Shock; AKI (Acute Kidney Injury) Due to Trauma; AKI - Acute Kidney Injury

Summary: acute kidney injury (aki) is a complication of traumatic haemorrhagic shock (ths) and together these conditions increase mortality risk. although septic shock patients who develop severe aki are known to develop hypoperfusion of the renal cortex, little is known regarding intra-renal perfusion changes in ths. the aim of the current study is to investigate the effects of ths on renal microcirculatory perfusion.


Eligibility criteria:
inclusion criteria: * age \> 18 years * within 24 hours of icu admission following traumatic injury * received any blood products during initial resuscitation * lactate \> 2 mmol/l at any stage prior to study enrolment exclusion criteria: * known intolerance to sonovue or any other ultrasound contrast agent * patients with un-survivable injuries / not expected to survive 24 hours in whom the intent of treatment is palliative * known ckd 4 or end stage renal failure * pregnancy
a clinical evaluation of the orsense non-invasive blood hb/hct measurement instrument, the hemo-monitor nbm200/mp

Conditions: Anemia

Summary: the purpose of the study is to define the precision, accuracy and variability of the nbm-200 system in non invasive blood hemoglobin (hb) measurements relative to the laboratory blood analyzer by comparing two consecutive hb values obtained by the nbm system to venous values.

each subject will be placed in a comfortable position in a temperature regulated room. participants will have two consecutive non invasive (nbm) measurements taken which involves inserting the thumb into a ring shaped sensor. after each non invasive measurement the sensor will be removed. each measurement takes approximately 85 seconds and involves the finger cuff inflating (to over systolic pressure) and deflating several times in quick successions in order to measure and calculate the hb values. the two non invasive measurements will be performed using the same finger. after the nbm system testing is complete and recorded, the subject will have a venous (venipuncture) blood sample collected in order to provide two blood tests performed on two different models of routine automated complete blood count or hb blood analyzers.

Eligibility criteria:
inclusion criteria: * participants aged 18 years and over exclusion criteria: * participants under the age of 18 years * patients with significant deformity, degenerative changes or oedema of the fingers or hand * patients with localized infection, ulceration or skin breaks involving the fingers * patients with vascular disease or raynaud's phenomenon affecting the fingers (vasospasm) * participants who are unable to give informed written consent

Keywords: accurte hb noninvasive measurement
autophagy in systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus

Summary: systemic lupus erythematosus is systemic autoimmune disease characterized by a wide range of clinical manifestations, from skin and mucosal lesions to severe injuries in the central nervous system, kidneys and other organs. the presence of high titres of autoantibodies against nuclear components, immune complexes deposition, complement deficiency and lymphocytes infiltration in affected tissues, which causes tissue and organ damage are the main characteristics of the disease. nowadays, many studies elucidate the essential role of autophagy in the occurrence, development and severity of systemic lupus erythematosus.

autophagy is a highly conserved lysosome-mediated catabolic process. it can remove unwanted cytoplasmic components, such as long-lived and/or misfolded proteins, damaged organelles, playing an important role in maintaining cellular homeostasis and cell survival in stress conditions, such as nutrient deprivation and hypoxia. recently, autophagy is implicated in nearly all steps of both innate and adaptive immune responses, including neutrophil extracellular trap and inflammasome formation, pathogen recognition, lymphocyte and monocyte development and function, antigen processing and presentation, type i interferon production and inflammatory regulation, thus playing an important part in maintaining the balance of immune system. autophagy is divided into three major types: macroautophagy, microautophagy, and chaperone-mediated autophagy, with macroautophagy being the most investigated and understood. disturbances in autophagy have been implicated in chronic inflammatory diseases and several autoimmune diseases, including systemic lupus erythematosus, multiple sclerosis, crohn's disease and rheumatoid arthritis. several regulatory factors that may play key roles in autophagy processes have been discovered in recent years, such as beclin1, which is the key regulatory factor in the autophagy startup process, microtubule-associated protein-light chain 3, autophagy-related gene 5, which are components of autophagosomes.

Eligibility criteria:
inclusion criteria: * patients who fulfilled at least four criteria of systemic lupus erythematosus according to american college of rheumatology exclusion criteria: * pregnancy or lactation. * coexistence of other autoimmune diseases.
programming by estrogen treatment in gonadotropin releasing hormone antagonist protocol

Conditions: Infertility

Summary: the purpose of this study is to determine if pretreatment with estrogen can assist in the planning and programming of in vitro fertilization treatments.

a randomised controlled trial in which study group will be given estrogen derivative before ovarian stimulation in gnrh antagonist protocol and compared to the classical gnrh agonist protocol.estrogen will be given p.o , "progynova' , in a dose of 2 mg /d, starting day 2 of menses and until first monday to follow. main outcome measure will be ability to control the ovum pickup day, calculated as a rate of ideal pickups divided by the entire pickup number. all women enrolled will be under 38 years of age, with a clear indication for ivf other than ovulatory dysfunction. women with past 4 treatment failures will be excluded as well as cases in which sperm achieved in surgical methods.

Eligibility criteria:
inclusion criteria: * ivf treatment in the following indications: male, mechanical, unexplained * age\<38 years * treatment cycle number 1-4 exclusion criteria: * ovulatory disorder as an indication for ivf * repeated failure in previous ivf treatments (\> than 4 cycles) * sperm used for treatment was retrieved by surgical procedure

Keywords: infertility, ivf, estrogen
estradiol and fear extinction in anorexia nervosa (an)

Conditions: Anorexia Nervosa

Summary: the purpose of this study is to determine whether estrogen may help reduce fear of high calorie-density foods in weight-restored women with anorexia nervosa (an).


Eligibility criteria:
inclusion criteria (an): * previous diagnosis of recent an with bmi of \<18.5 (within past year) * current bmi \> 19.0 and \< 23.0 kg/m2 * amenorrhea or oligomenorrhea inclusion criteria (healthy controls): * bmi \> 19 \< 23 kg/m2 * taking hormone-based contraceptives for a period of one month or more * eating disorders symptom scores within one standard deviation of healthy controls exclusion criteria (an): * any medical or psychiatric problem requiring urgent medical or psychiatric attention, including acute suicidality * history of breast cancer, deep vein thrombosis, pulmonary embolism, myocardial infarction or stroke, diabetes, liver disease, known thrombophilic disease * currently taking estrogen or progesterone medication * tobacco use greater than 1 pack per week * use of st. john's wort, phenobarbital, phenytoin, carbamazepine, rifampin, and dexamethasone can all decrease plasma estrogen level because they are cyp3a4 inducers. cimetidine, erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice as these may increase plasma estrogen, potentially increasing the presence of side effects * pregnant, lactating or unwilling to use appropriate birth control (which may include abstinence) to prevent pregnancy for the duration of study participation (i.e. up to 4 weeks) * allergy to estradiol or medroxyprogesterone or ingredients in food items used for test meals * undiagnosed, abnormal vaginal bleeding exclusion criteria (healthy controls): * ever diagnosed with an eating disorder * any medical or psychiatric problem requiring urgent medical or psychiatric attention, including acute suicidality * pregnant, lactating or unwilling to use appropriate birth control (which may include abstinence) to prevent pregnancy for the duration of study participation (i.e. up to 4 weeks) * food allergies to items in the test meal

Keywords: estrogen anxiety amenorrhea eating disorders
evaluation of patient reported outcomes (pro) after total knee arthroplasty (tka) under spinal anesthesia

Conditions: Knee Injuries

Summary: the purpose of this study will be to evaluate and compare patients undergoing total knee arthroplasty (tka) with sensor guidance versus that of a standard technique. each patient will be assessed for the difference between passive, soft tissue controlled, pressure balance and muscle activated pressure balance.


Eligibility criteria:
inclusion criteria: * patients will be screened for eligibility based on whether they have chronic knee pain as a result of an arthritis-related condition. * patient with chronic knee pain who is indicated for total hip or knee replacement surgery * patient is at least 50 years of age * patient is willing to participate in pre- and postoperative surveys exclusion criteria: * failure to complete pre-operative surveys. * revision total knee arthroplasty * prior ipsilateral knee surgery such as ligament reconstruction or osteotomy * contralateral total knee arthroplasty * prior tibial plateau fracture * ligamentous insufficiency * history of fibromyalgia, chronic fatigue syndrome

Keywords: total knee replacement arthroplasty
a phase 2 trial of opc-64005 for major depressive disorder

Conditions: Major Depressive Disorder

Summary: the objective of the trial is to compare the efficacy of opc-64005 at 20 mg vs placebo and to assess the safety and pharmacokinetics of opc-64005 at 10 and 20 mg in patients with major depressive disorder (mdd).the primary endpoint is the mean change from baseline in montgomery-åsberg depression rating scale (madrs) total score at week 6 of the double-blind treatment period in the opc-64005 20-mg group compared with the placebo group


Eligibility criteria:
inclusion criteria: * patients with a dsm-5 classification-based diagnosis of "major depressive disorder, single episode" or "major depressive disorder, recurrent episode" with the current episode persisting for ≥4 weeks to ≤1 year * patients with a total score of ≥18 on the 17-item hamilton rating scale for depression (ham-d) exclusion criteria: * patients with a diagnosis of any of the following diseases according to dsm-5 neurocognitive disorders, history or complication of schizophrenia spectrum or other psychotic disorder, history or complication of bipolar and related disorders, feeding and eating disorders, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, personality disorders, neurodevelopmental disorders, substance-related and addictive disorders (within 180 days prior to informed consent) * patients exhibiting mood-incongruent psychotic features in the current major depressive episode * patients who, in the opinion of the investigator or subinvestigator, are judged to have treatment-resistant depression, ie, a certain degree of therapeutic effect is not obtained by administration of 2 or more antidepressants having different mechanisms of action at sufficient doses for at least 6 weeks for the current major depressive episode * patients receiving augmentation treatment, such as antipsychotics, for the current major depressive episode (excluding the use of sulpiride for depression/depressive state or gastric/duodenal ulcer)
pethema multiple myeloma 2000

Conditions: Multiple Myeloma

Summary: the study objectives are to investigate the toxicity and the bumel response rate; in patients who reach the cr after autotransplantation, investigate if negativization of if, influences in disease evolution; in patients in pr after autotransplantation, analyze if the second intensive procedure is capable of increasing the response rate and increasing the survival so that patients who reached the cr with the first transplantation; patients with mm primarily resistant to the chemotherapy, investigate the efficacy of a double transplantation; patients submitted to double transplantation, control the efficacy of the second transplantation in front of allogenic transplantation.


Eligibility criteria:
inclusion criteria: * less 70 years * ecog 0-2 * symptomatic mm (pain, anemia, infection, haemorrhage, loss of weight, hypercalcemia, extramedulary plasmocytoma, creatinine \>2 mg/dl). * no previous chemotherapy exclusion criteria: * \>70 years * ecog 3-4 * myeloma quiescent * cardiopathy * liver disfunction * hiv+ * hepatitis b-c + * previous chemotherapy

Keywords: multiple myeloma alternating chemotherapy transplantation
prehypertension labeling

Conditions: Prehypertension

Summary: the purpose of this study is to find out whether labeling adults with prehypertension has negative effects on clinic blood pressure and quality of life 3 months after diagnosis.

previous research has shown that a diagnosis of hypertension is associated with subsequent increases in resting blood pressure, and there is preliminary evidence of a cross-sectional association between hypertension labeling and the white coat effect. the white coat effect may be particularly problematic in prehypertensives, because a small elevation in clinic blood pressure could result in crossing the diagnostic cutoff for hypertension, potentially leading to misdiagnosis and unnecessary treatment. this study will examine effects of prehypertension labeling on clinic and ambulatory blood pressure, and will examine potential psychological mediators of these associations.

Eligibility criteria:
inclusion criteria: * at least 18 years * average screening systolic blood pressure of 120-139 mmhg or diastolic blood pressure of 80-89 mmhg * average screening systolic blood pressure below 140 mmhg and diastolic blood pressure below 90 mmhg * able to read and write in english exclusion criteria: * past diagnosis of hypertension, prehypertension, or high blood pressure * current or past use of antihypertensive medications * diabetes * renal disease * cardiovascular disease * current participation in another hypertension-related clinical trial

Keywords: prehypertension blood pressure screening white coat effect